Yang et al. [164] have demonstrated that fucoidan not only enhances the gut microbiome diversity, but also influences metabolic pathways in tumor-bearing hosts, contributing to a more robust antitumor response when combined with PD-1 inhibitors. The gene discussed is PDCD1; the disease is neoplasm.